Rigidity in social and emotional memory in the R6/2 mouse model of Huntington's disease.

Neurobiol Learn Mem

Department of Pharmacology, University of Cambridge, Tennis Court Road, CB2 1PD Cambridge, UK.

Published: May 2008

Four experiments were conducted to examine social and emotional memory in the R6/2 transgenic mouse model of Huntington's disease. First, R6/2 mice were tested in a social transmission of food preference task where they had to acquire a preference for a flavoured food (acquisition) and subsequently to learn a preference for a different flavour (shifted reinforcement). R6/2 mice performed well in the acquisition trial. However, they were impaired in the shifted reinforcement trial and perseverated on the first preference learned. Second, mice were trained in an inhibitory avoidance paradigm, with either one or two footshocks delivered during the training. WT mice given one footshock showed retention levels lower than those of mice trained with two footshocks. By contrast, there was no difference in retention levels of R6/2 mice given either one or two footshocks. Third, mice were tested in an active avoidance task that paired a mild footshock with a warning light. R6/2 mice had a strong age-dependent deficit in this task. Finally, mice were tested in a conditioned taste aversion task that paired a saccharine solution with a nausea-inducing agent (LiCl). R6/2 mice displayed normal aversion, however this was not extinguished following repeated exposure to saccharine solution alone. Our data show that while R6/2 mice have functional hippocampus-based memory, they have deficits in striatum-based memory skills. Further, social and emotional memories appear to be encoded in a rigid way that is not influenced by subsequent learning or by arousal levels.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nlm.2007.10.009DOI Listing

Publication Analysis

Top Keywords

r6/2 mice
24
social emotional
12
mice tested
12
mice
11
emotional memory
8
r6/2
8
memory r6/2
8
mouse model
8
model huntington's
8
huntington's disease
8

Similar Publications

Pleiotropic effects of mutant huntingtin on retinopathy in two mouse models of Huntington's disease.

Neurobiol Dis

December 2024

Department of Physiology & Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address:

Huntington's disease (HD) is caused by the expansion of a CAG repeat, encoding a string of glutamines (polyQ) in the first exon of the huntingtin gene (HTTex1). This mutant huntingtin protein (mHTT) with extended polyQ forms aggregates in cortical and striatal neurons, causing cell damage and death. The retina is part of the central nervous system (CNS), and visual deficits and structural abnormalities in the retina of HD patients have been observed.

View Article and Find Full Text PDF

There is a growing consensus that brain development in Huntington's disease (HD) is abnormal, leading to the idea that HD is not only a neurodegenerative but also a neurodevelopmental disorder. Indeed, structural and functional abnormalities have been observed during brain development in both humans and animal models of HD. However, a concurrent study of cortical and striatal development in a genetic model of HD is still lacking.

View Article and Find Full Text PDF
Article Synopsis
  • - Huntington's disease (HD) is a genetic neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene, leading to the accumulation of harmful mutant proteins in nerve cells.
  • - The NLRP3 inflammasome plays a crucial role in inflammation and its overactivation contributes to neurodegeneration in HD; inhibiting it showed potential benefits in mice by reducing toxic inflammation and neuronal damage.
  • - Antcin-H, a compound derived from the medicinal fungus Antrodia cinnamomea, was found to decrease neuroinflammation and toxicity while improving motor function and survival rates in a mouse model of HD, indicating its potential as a therapeutic option.
View Article and Find Full Text PDF

Huntington's disease (HD) is a progressive neurodegenerative disorder with no cure, characterized by significant neurodegeneration of striatal GABAergic medium spiny neurons (MSNs). Early stages of the disease are characterized by the loss of dopamine 2 receptor-expressing MSNs (D2 MSNs) followed by degeneration of dopamine 1 receptor-expressing MSNs (D1 MSNs), leading to aberrant basal ganglia signaling. While the early degeneration of D2 MSNs and impaired GABAergic transmission are well-documented, potassium chloride cotransporter 2 (KCC2), a key regulator of intracellular chloride (Cl), and therefore GABAergic signaling, has not been characterized in D1 and D2 MSNs in HD.

View Article and Find Full Text PDF
Article Synopsis
  • Recent research indicates that blocking the interaction between valosin-containing protein (VCP) and mutant huntingtin (mtHtt) can help prevent mitochondrial damage in Huntington's disease models.
  • A newly developed protein-like polymer (PLP) has shown effectiveness in cellular and animal models, significantly inhibiting mitochondrial destruction and proving more stable than control oligopeptides.
  • PLP has a remarkably longer circulation half-life (152 hours) and outperforms free peptide in efficacy tests, suggesting it could be a promising platform for developing treatments for central nervous system disorders.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!